Advanced search
Publication Cover
Expert Review of Proteomics Volume 5, 2008 - Issue 2
Submit an article Journal homepage
208
Views
27
CrossRef citations to date
0
Altmetric
Review

α-synuclein and Parkinson’s disease: a proteomic view

Mauro Fasano Professor of Biochemistry, Department of Structural & Functional Biology, & Centre of Neuroscience, University of Insubria, Via Alberto da Giussano 12, 21052 Busto Arsizio, Italy. [email protected]
&
Leonardo Lopiano Professor of Neurology, Department of Neuroscience, University of Torino, Via Cherasco 15, 10126 Torino, Italy. [email protected]
Pages 239-248 | Published online: 09 Jan 2014

References

  • Lang AE, Lozano AM. Parkinson’s disease. N. Engl. J. Med.339, 1044–1053 (1998).
  • Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson’s disease. Progr. Neurobiol.62, 63–88 (2000).
  • Cookson MR. Pathways to Parkinsonism. Neuron37, 7–10 (2003).
  • Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch. Neurol.62, 353–357 (2005).
  • Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol. Med.12, 521–528 (2006).
  • Thomas B, Beal MF. Parkinson’s disease. Hum. Mol. Genet.16(Spec. No. 2), R183–R194 (2007).
  • Olanow CW. The pathogenesis of cell death in Parkinson’s disease – 2007. Mov. Disord.22(Suppl. 17), S335–S342 (2007).
  • McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann. Neurol.53(Suppl. 3), S73–S84 (2003).
  • Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin–proteasome system and Parkinson’s diseases. Exp. Neurol.191(Suppl. 1), S17–S27 (2005).
  • Betarbet R, Canet-Aviles RM, Sherer TB et al. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system. Neurobiol. Dis.22, 404–420 (2006).
  • McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol. Aging27, 530–545 (2006).
  • Lewy FH. Handbuch der Neurologie (3rd Edition). Lewandowsky M, Abelsdorff G (Eds). Springer, Berlin, Germany 920–933 (1912).
  • Spillantini MG, Schmidt ML, Lee VM et al. A-synuclein in Lewy bodies. Nature388, 839–840 (1997).
  • Goedert M. A-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci.2, 492–501 (2001).
  • Hirsch E, Graybiel A, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature334, 345–348 (1988).
  • Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson’s disease. Brain Res.581, 283–291 (1992).
  • Kastner A, Hirsch EC, Lejeune O et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J. Neurochem.59, 1080–1089 (1992).
  • Youdim MB, Ben-Shachar D, Riederer P. The enigma of neuromelanin in Parkinson’s disease substantia nigra. J. Neural Transm. Suppl.43, 113–122 (1994).
  • Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci.26, 578–580 (2003).
  • Fedorow H, Tribl F, Halliday G et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Progr. Neurobiol.75, 109–124 (2005).
  • Ostrerova N, Petrucelli L, Farrer M et al. α-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci.19, 5782–5791 (1999).
  • Kim TD, Paik SR, Yang CH, Kim J. Structural changes in α-synuclein affect its chaperone-like activity in vitro. Protein Sci.9, 2489–2496 (2000).
  • Steece-Collier K, Maries E, Kordower JH. Etiology of Parkinson’s disease: genetics and environment revisited. Proc. Natl Acad. Sci. USA99, 13972–13974 (2002).
  • Bussell R Jr, Eliezer D. A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol.329, 763–778 (2003).
  • Bisaglia M, Tessari I, Pinato L et al. A topological model of the interaction between α-synuclein and sodium dodecyl sulfate micelles. Biochemistry44, 329–339 (2005).
  • Golbe LI. α-synuclein and Parkinson’s disease. Mov. Disord.14, 6–9 (1999).
  • Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson’s disease. Neurobiol. Dis.7, 240–250 (2000).
  • Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci.3, 932–942 (2002).
  • Bonifati V, Oostra BA, Heutink P. Unraveling the pathogenesis of Parkinson’s disease – the contribution of monogenic forms. Cell. Mol. Life Sci.61, 1729–1750 (2004).
  • Gasser T. Genetics of Parkinson’s disease. Curr. Opin. Neurol.18, 363–369 (2005).
  • Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson’s disease and parkinsonism. Ann. Neurol.60, 389–398 (2006).
  • Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science276, 2045–2047 (1997).
  • Krüger R, Kuhn W, Muller T et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat. Genet.18, 106–108 (1998).
  • Zarranz JJ, Alegre J, Gomez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol.55, 164–173 (2004).
  • Chartier-Harlin MC, Kachergus J, Roumier C et al. A-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet364, 1167–1169 (2004).
  • Ibanez P, Bonnet AM, Debarges B et al. Causal relation between α-synuclein gene duplication and familial Parkinson’s disease. Lancet364, 1169–1171 (2004).
  • Farrer M, Kachergus J, Forno L et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol.55, 174–179 (2004).
  • Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson’s disease. Science302, 841 (2003).
  • Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation. Neuroscience97, 279–284 (2000).
  • Tabrizi SJ, Orth M, Wilkinson JM et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet.9, 2683–2689 (2000).
  • Przedborski S, Jackson-Lewis VR. Free Radicals in Brain Pathophysiology. Poli G, Cadenas E, Packer L (Eds). Marcel Dekker, NY, USA 273–290 (2000).
  • Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild type or mutant α-synuclein on cell susceptibility to insult. J. Neurochem.76, 998–1005 (2001).
  • Tanaka Y, Engelender S, Igarashi S et al. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet.10, 919–926 (2001).
  • Junn E, Mouradian MM. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett.320, 146–150 (2002).
  • Xu J, Kao SY, Lee FJ et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med.8, 600–606 (2002).
  • Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest.111, 163–169 (2003).
  • Maguire-Zeiss KA, Short DW, Federoff HJ. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res. Mol. Brain Res.134, 18–23 (2005).
  • Cookson MR, van der Brug M. Cell systems and the toxic mechanism(s) of α-synuclein. Exp. Neurol.209, 5–11 (2008).
  • Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Disc.3, 205–214 (2004).
  • Berg D, Youdim MB, Riederer P. Redox imbalance. Cell Tissue Res.318, 201–213 (2004).
  • Yu S, Uéda K, Chan P. α-synuclein and dopamine metabolism. Mol. Neurobiol.31, 243–254 (2005).
  • Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson’s disease. J. Neurochem.96, 909–916 (2006).
  • Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies. J. Neural Transm.113, 769–774 (2006).
  • Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease. Curr. Opin. Neurobiol.17, 331–337 (2007).
  • Zecca L, Gallorini M, Schünemann V et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem.76, 1766–1773 (2001).
  • Volles MJ, Lee SJ, Rochet JC et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry40, 7812–7819 (2001).
  • Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry41, 4595–4602 (2002).
  • Lashuel HA, Petre BM, Wall J et al. α-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol.322, 1089–1102 (2002).
  • Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science294, 1346–1349 (2001).
  • Rochet JC, Outeiro TF, Conway KA et al. Interactions among α-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease. J. Mol. Neurosci.23, 23–24 (2004).
  • Montine TJ, Farris DB, Graham DG. Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation. J. Neuropathol. Exp. Neurol.54, 311–319 (1995).
  • Hao R, MacDonald RG, Ebadi M, Schmit JC, Pfeiffer RF. Stable interaction between G-actin and neurofilament light subunit in dopaminergic neurons. Neurochem. Int.31, 825–834 (1997).
  • Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L. Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to α-synuclein. Neurochem. Int.42, 603–606 (2003).
  • Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318, 121–134 (2004).
  • Michell AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson’s disease. Brain127, 1693–1705 (2004).
  • Rachakonda V, Pan TH, Le WD. Biomarkers of neurodegenerative disorders: how good are they? Cell Res.14, 347 (2004).
  • Dorsey ER, Holloway RG, Ravina BM. Biomarkers in Parkinson’s disease. Expert Rev. Neurother.6, 823–831 (2006).
  • Schulenborg T, Schmidt O, van Hall A et al. Proteomics in neurodegeneration – disease driven approaches. J. Neural Transm.113, 1055–1073 (2006).
  • Sheta EA, Appel SH, Goldknopf IL. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev. Proteomics3, 45–62 (2006).
  • Fasano M, Bergamasco B, Lopiano L. The proteomic approach in Parkinson’s disease. Proteomics Clin. Appl.1, 1428–1435 (2007).
  • Jin J, Hulette C, Wang Y et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics5, 1193–1204 (2006).
  • Basso M, Giraudo S, Lopiano L et al. Proteome analysis of mesencephalic tissues: evidence for Parkinson’s disease. Neurol. Sci.24, 155–156 (2003).
  • Basso M, Giraudo S, Corpillo D et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics4, 3943–3952 (2004).
  • Tribl F, Gerlach M, Marcus K et al. “Subcellular proteomics” of neuromelanin granules isolated from the human brain. Mol. Cell. Proteomics4, 945–957 (2005).
  • Tribl F, Marcus K, Bringmann G et al. Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J. Neural Transm.113, 1041–1054 (2006).
  • Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci.6, 8 (2008).
  • Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res.967, 152–160 (2003).
  • Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson’s disease. Proc. Natl Acad. Sci. USA104, 18742–18747 (2007).
  • Hattori F, Oikawa S. Peroxiredoxins in the central nervous system. Subcell. Biochem.44, 357–374 (2007).
  • Choi J, Sullards MC, Olzmann JA et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem.281, 10816–10824 (2006).
  • Cohen N, Betts DR, Rechavi G, Amariglio N, Trakhtenbrot L. Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-N-SH neuroblastoma cell line. Cancer Genet. Cytogenet.143, 80–84 (2003).
  • Gomez-Santos C, Ferrer I, Santidrian AF et al. DA induces autophagic cell death and α-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res.73, 341–350 (2003).
  • Colapinto M, Mila S, Giraudo S et al. α-synuclein protects SH-SY5Y cells from dopamine toxicity. Biochem. Biophys. Res. Commun.349, 1294–1300 (2006).
  • Albani D, Peverelli E, Rametta R et al. Protective effect of TAT-delivered α-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J.18, 1713–1715 (2004).
  • Choi HS, Lee SH, Kim SY et al. Transduced Tat-α-synuclein protects against oxidative stress in vitro and in vivo. J. Biochem. Mol. Biol.39, 253–262 (2006).
  • Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science299, 256–259 (2002).
  • Martinat C, Shendelman S, Jonason A et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary parkinsonism. PLoS Biol.2, E327 (2004).
  • Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol.2, E362 (2004).
  • Xu J, Zhong N, Wang H et al. The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet.14, 1231–1241 (2005).
  • Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T α-synuclein toxicity. J. Biol. Chem.280, 43150 (2005).
  • Zhou Y, Gu G, Goodlett DR et al. Analysis of α-synuclein-associated proteins by quantitative proteomics. J. Biol. Chem.279, 39155–39164 (2004).
  • Jin J, Li GJ, Davis J et al. Identification of novel proteins interacting with both α-synuclein and DJ-1. Mol. Cell Proteomics6, 845–859 (2007).
  • Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci.3, 1301–1306 (2000).
  • Liu J, Zhou Y, Wang Y, Fong H, Murray TM, Zhang J. Identification of proteins involved in microglial endocytosis of α-synuclein. J. Proteome Res.6, 3614–3627 (2007).
  • Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. A-synuclein cooperates with CSPa in preventing neurodegeneration. Cell123, 383–396 (2005).
  • Larsen KE, Schmitz Y, Troyer MD et al. α-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci.26, 11915–11922 (2006).
  • Mosharov EV, Staal RG, Bové J et al. α-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci.26, 9304–9311 (2006).
  • Feany MB, Bender WW. A Drosophila model of Parkinson’s disease. Nature404, 394–398 (2000).
  • Cooper AA, Gitler AD, Cashikar A et al. α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science313, 324–328 (2006).
  • Kuwahara T, Koyama A, Gengyo-Ando K et al. Familial Parkinson mutant α-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem.281, 334–340 (2006).
  • Ichibangase T, Saimaru H, Takamura N et al. Proteomics of Caenorhabditis elegans over-expressing human α-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson’s disease stages. Biomed. Chromatogr.22(3), 232–234 (2007).
  • Fulga TA, Elson-Schwab I, Khurana V et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol.9, 139–148 (2007).
  • Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Protein expression in a Drosophila model of Parkinson’s disease. J. Proteome Res.6, 348–357 (2007).
  • Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Lifetime proteomic profiling of an A30P α-synuclein Drosophila model of Parkinson’s disease. J. Proteome Res.6, 3729–3738 (2007).
  • Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron39, 889–909 (2003).
  • Palacino JJ, Sagi D, Goldberg MS et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem.279, 18614–18622 (2004).
  • Chung KK, Thomas B, Li X et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science304, 1328–1331 (2004).
  • Goldberg MS, Fleming SM, Palacino JJ et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem.278, 43628–43635 (2003).
  • Fountoulakis M, Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis27, 1556–1573 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.